Explore Cell Therapy

14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53.
In Part I: Expanding Access to Older Patients, guests explore major advances in transplant for older patients with MDS, highlighting the recent expansion of coverage through the Centers for Medicare and Medicaid Services (CMS), a significant milestone driven by recent studies that demonstrate the safety and efficacy of HCT in patients over 65 years old.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

14 - HCT Across MDS Genetic Subtypes, Part II: The Role of Genetics and Early Consult

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53. 
In Part II, experts stress the importance of early consultation to optimize treatment decisions and ensure equity in access to HCT for older patients in need of a curative treatment option.   
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

13 - Optimizing Donor Searches in HCT, Part II: Overcoming Barriers

This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.  
In Part II: Overcoming Barriers, the experts review implications for the future of donor search optimization, transplant access and health equity in an increasingly diverse patient population. 
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

13 - Optimizing Donor Searches in HCT, Part I: Strategies and Considerations

This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.  
In Part I: Strategies and Considerations, the experts discuss strategies to prioritize alternative donor sources to ensure that more patients receive HCT at optimal timepoints. 
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

12 - Streamlining HCT Referrals, Part I: Overcoming Barriers through Coordinated Care

In this two-part episode, Jonathan Fish, MD, with Cohen Children’s Medical Center and Joanna Pierro, DO, with Staten Island University Hospital discuss the transformative impact of a streamlined referral process to simplify setting up consultations for HCT and cell therapy.
In Part I: Overcoming Barriers through Coordinated Care, guests explore how this simple system created using RedCap software can help overcome logistical barriers and enhance coordinated care through a single point of entry for referrals.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

12- Streamlining HCT Referrals, Part II: Assessing the Impact and Future State

In this two-part episode, Jonathan Fish, MD, with Cohen Children’s Medical Center and Joanna Pierro, DO, with Staten Island University Hospital discuss the transformative impact of a streamlined referral process to simplify setting up consultations for HCT and cell therapy.
In Part II: Assessing the Impact and Future State, experts stress how early logistical planning and improved communication channels can increase referral volumes, optimize patient outcomes, and support the introduction of groundbreaking new cell and gene therapy options for patients.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

11 - First-line BMT for Severe Aplastic Anemia, Pt. 2: Future Research and Care Coordination

In this two-part episode, Amy DeZern, MD, MHS, with Johns Hopkins and Christin DeStefano, MD, with Uniformed Services University discuss bone marrow transplant as a first-line treatment for severe aplastic anemia, moving beyond the limitations of traditional immunosuppressive therapies for a curative treatment option.
In Part II: Future Research and Care Coordination, experts underscore the critical importance of early referral and coordination between hematology/oncology and transplant centers while looking ahead at the exciting research and clinical trials yet to come.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

11 - First-line BMT for Severe Aplastic Anemia, Pt. 1: Outcomes and Equity

In this two-part episode, Amy DeZern, MD, MHS, with Johns Hopkins and Christin DeStefano, MD, with Uniformed Services University discuss bone marrow transplant as a first-line treatment for severe aplastic anemia, moving beyond the limitations of traditional immunosuppressive therapies for a curative treatment option.
In Part I: Outcomes and Equity, guests explore the benefits of haploidentical transplant, noting quicker recovery times and reduced complications compared to past methods. These advancements are particularly impactful for diverse populations, including military personnel.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

10 – Trends in HCT Equity, Access and Outcomes, Pt. 2: Personalization and Future Care

In this two-part episode, Rachel Phelan, MD, MPH, with the Medical College of Wisconsin and Rafeek Yusuf, MD, PhD, with NMDP discuss the latest trends in access and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation according to their recent CIBMTR (Center for International Blood and Marrow Transplant Research) report.
 
In Part II: Personalization and Future Care, guests highlight the importance of holistic, personalized care throughout the patient journey as we navigate the complexities of transplantation, advocate for precision medicine, and envision a future with even more inclusive and effective health care solutions.
 
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

10 – Trends in HCT Equity, Access and Outcomes, Pt. 1: Improvements and Challenges

In this two-part episode, Rachel Phelan, MD, MPH, with the Medical College of Wisconsin and Rafeek Yusuf, MD, PhD, with NMDP discuss the latest trends in access and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation according to their recent CIBMTR (Center for International Blood and Marrow Transplant Research) report.
 
In Part I: Improvements and Challenges, experts illuminate significant strides in GVHD prevention and the use of haploidentical and mismatched unrelated donor sources to close gaps in equity. We explore the multifaceted barriers hindering equitable transplantation – from socioeconomic and health literacy challenges to donor availability.
 
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.